🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Advanced Prostate Cancer

A Study of MT-4561 in Patients With Various Advanced Solid Tumors NCT06943521Phase 1, Phase 26 sites📍 Los Angeles📍 Grand Rapids📍 Columbus Tanabe Pharma America, Inc. · Tests: MT-4561 A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer NCT06609005Phase 1, Phase 222 sites📍 Scottsdale📍 Newport Beach📍 Orange Shenzhen Ionova Life Sciences Co., Ltd. · Tests: INV-9956 Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors NCT07288359Phase 1, Phase 216 sites📍 Atlanta📍 Nashville📍 San Antonio Novartis Pharmaceuticals · Tests: GVV858, Fulvestrant, Letrozole SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization NCT06389097n/a1 site📍 Baltimore Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Tests: Radium-223, 177Lu-DOTATATE, 177Lu-PSMA-617 A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors NCT05932862Phase 116 sites📍 Fountain Valley📍 Jacksonville📍 Orlando Exelixis · Tests: XL309, Olaparib Hypofractionated Radiotherapy With a Focal Microboost for High-Risk and Locally Advanced Prostate Cancer NCT07325721Phase 21 site📍 Charleston Medical University of South Carolina · Tests: Hypofractionated radiation with a microboost Imaging of Solid Tumors Using 18F-TRX NCT06942104Phase 11 site📍 San Francisco Rahul Aggarwal · Tests: 18F-TRX, Positron Emission Tomography (PET)/Computerized tomography (CT), Tumor Biopsy, Blood Specimen Collection A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1) NCT07723248Phase 312 sites📍 Coral Springs📍 Jeffersonville📍 Holland ORIC Pharmaceuticals · Tests: Rinzimetostat, Darolutamide, Enzalutamide, Docetaxel European Registry of Next Generation Imaging in Advanced Prostate Cancer NCT06866782n/a24 sites📍 Leuven📍 Lille📍 Lyon Fundacio Puigvert · Tests: Imaging Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer NCT07667400Phase 1, Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: SX-682, DTX A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors NCT06440005Phase 17 sites📍 Los Angeles📍 Sarasota📍 St Louis Angiex, Inc. · Tests: AGX101 Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors NCT06666270Phase 12 sites📍 Zhengzhou📍 Shanghai Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd · Tests: SYN818 Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors NCT07145255Phase 1, Phase 27 sites📍 San Francisco📍 Grand Rapids📍 East Brunswick MBrace Therapeutics · Tests: ADC Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial NCT06499870Phase 21 site📍 Chicago Sean Sachdev · Tests: Biopsy, Biospecimen Collection, Computed Tomography, Enzalutamide, Fluorine F 18 Piflufolastat Optimizing Prostate Cancer Treatment in Men With Advanced Local Disease NCT03836196NA1 site📍 Vancouver British Columbia Cancer Agency · Tests: LDR Brachytherapy and External Beam Radiation Therapy Safety and Early Efficacy of Radical Prostatectomy for Newly Diagnosed Very High Risk Locally Advanced and Oligometastatic Prostate Cancer NCT02971358NA1 site📍 Vienna Medical University of Vienna · Tests: Radical prostatectomy A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer NCT07198633Phase 1, Phase 21 site📍 Tianjin Qilu Pharmaceutical Co., Ltd. · Tests: QLC5508, abiraterone acetate, enzalutamide, QLH12016 A Study of NX-1607 in Adults With Advanced Malignancies NCT05107674Phase 117 sites📍 Duarte📍 Los Angeles📍 San Francisco Nurix Therapeutics, Inc. · Tests: NX-1607, Paclitaxel Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation NCT04890613Phase 18 sites📍 Santa Monica📍 Tampa📍 Boston Senhwa Biosciences, Inc. · Tests: CX-5461 A Study of JNJ-98768111 in Participants With Advanced Prostate Cancer NCT07746713Phase 15 sites📍 Sarasota📍 Grand Rapids📍 West Valley City Janssen Research & Development, LLC · Tests: JNJ-98768111 A Study of Meaning-Centered Therapy for Mexican Adults With Advanced Cancer NCT07225309NA2 sites📍 New York📍 Mexico City Memorial Sloan Kettering Cancer Center · Tests: Meaning-Centered Psychotherapy for Latinos /MCP-L EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors NCT07410676Phase 1, Phase 21 site📍 Beijing Essen Biotech · Tests: EBNK-001 + IL-15 + Pembrolizumab ART-Pro: Clinical Trial Evaluating Biparametric MRI and Advanced, Quantitative Diffusion MRI for Detection of Prostate Cancer NCT06579417n/a5 sites📍 San Diego📍 San Francisco📍 Boston University of California, San Diego · Tests: RSI MRI Biological Markers and Advanced Imaging for Prostate Cancer Progression in Active Surveillance NCT06866041NA1 site📍 Milan Università Vita-Salute San Raffaele · Tests: mpMRI-targeted confirmatory biopsy Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors NCT07006727Phase 18 sites📍 Iowa City📍 Boston📍 Royal Oak Novartis Pharmaceuticals · Tests: 225Ac-ETN029, 111In-ETN029 Patient Decision-making About Precision Oncology in Veterans With Advanced Prostate Cancer NCT05396872NA1 site📍 San Francisco University of California, San Francisco · Tests: Participant Surveys, Mobile app Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer NCT06631521Phase 11 site📍 Orlando AdventHealth · Tests: Darolutamide, Relugolix, Radical Prostatectomy Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer NCT07641049Phase 11 site📍 Shenzhen Beijing Biotech · Tests: ETB-DualNK-01, Fludarabine, Cyclophosphamide A Study of DXC014 in Patients With Advanced Solid Tumors. NCT07177937Phase 15 sites📍 Beijing📍 Changsha📍 Nanchang Hangzhou DAC Biotechnology Co., Ltd. · Tests: DXC014 A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation NCT06952803Phase 3346 sites📍 Phoenix📍 Tucson📍 La Jolla AstraZeneca · Tests: Saruparib, Placebo, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT)
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy